Recent guidelines set forth by an interdisciplinary panel assembled by the American Thoracic Society sought to demystify primary ciliary dyskinesia and address 4 main diagnostic questions.
Intravenous antibiotics do not achieve greater sustained eradication of Pseudomonas aeruginosa in patients with cystic fibrosis compared with oral therapy.
Patients with cystic fibrosis who had pulmonary exacerbations treated with concomitant azithromycin and tobramycin had worse outcomes than those treated with tobramycin alone.
Preliminary evidence suggests that the CFHealthHub criteria are valid and useful in diagnosing chronic Pseudomonas aeruginosa in adults with cystic fibrosis.
In patients with cystic fibrosis, prolonged exposure to heat can lead to chloride-deficient metabolic alkalosis as a result of a loss of electrolytes through sweat.
The FDA has granted Breakthrough Therapy designation to brensocatib for the treatment of adults with non-cystic fibrosis bronchiectasis for reducing exacerbations.
In adults with cystic fibrosis, pancreatic status — that is, being pancreatic sufficient vs being pancreatic insufficient — has been shown to have a pronounced effect on the average rate of decline in lung function.
